Here, we report increased GFAP levels in the dlPFC and PCC of AD patients compared to those with no cognitive impairment, reinforcing the utility of GFAP as a blood-based biomarker in AD and confirming that measures collected from the periphery reflect processes happening in the CNS. This evidence concerns the gene GFAP and Alzheimer disease.